In the News

Landmark study published in the spine journal: annular closure superior to standard of care

The two-year results from a Level 1, randomized superiority study were published in The Spine Journal. Results from this landmark clinical study, that includes 554 patients from 6 countries, demonstrate superior outcomes when treating patients with large annular defects with Barricaid Annular Closure compared to discectomy alone. ABSTRACT SUMMARY Background context: Patients with large annular defects following […]

Read more

Best Paper Award SSA 2018 presented to Dr. Mark Arts

Dr. Mark Arts, a Dutch neurosurgeon from The Hague, delivered two podium presentations at the 2018 Spine Society of Australia 29th Annual Scientific Meeting, 27-29 April in Adelaide. One of his presented abstracts was elected as Best Paper of the 2018 Annual Scientific Meeting. Both talks were delivered in the Free Paper Session that focused on […]

Read more

Intrinsic Therapeutics announces the completion of a $49m financing

FUNDING SUPPORTS FDA APPROVAL PROCESS AND GLOBAL MARKET ACCESS  Boston, MA- May 10, 2017 -8:00am EST – Intrinsic Therapeutics, Inc. a medical device company that has developed a product to improve outcomes in lumbar discectomy patients, announced today that it recently closed a $49 million round of financing. The financing included a $28 million equity round […]

Read more

Intrinsic Therapeutics announces the filing of PMA application for its Barricaid Annular Closure device for lumbar discectomy patients

BOSTON, Dec. 21, 2016  Intrinsic Therapeutics, Inc. announced today that the filing of its Pre-Market Approval (PMA) application with the Food & Drug Administration (FDA) for the Barricaid® Annular Closure device is complete.  Barricaid has been shown to improve the outcomes of patients undergoing discectomy for herniated lumbar discs to relieve sciatica pain.  “Approximately 1 million […]

Read more

Intrinsic Therapeutics announces the enrollment of the 400th patient in landmark Barricaid randomized trial

Intrinsic Therapeutics today announced the enrollment of the 400th patient in a level 1, prospective, randomized, multi-center clinical trial evaluating the effectiveness of its Barricaid Prosthesis in improving outcomes for lumbar discectomy patients suffering from sciatica. The surgery was performed by Dr. Frederic Martens in Aalst, Belgium. The study is being conducted in Germany, Switzerland, Austria, and The Benelux with the goal […]

Read more

Intrinsic Therapeutics announces enrollment of 300th patient in Barricaid randomized trial

Intrinsic Therapeutics, a Medical Device Spine company, today announced a key milestone in a clinical study of its Barricaid® Prosthesis:  300 patients are now enrolled in a prospective, randomized, multi-center trial to definitively establish the safety and effectiveness of the implant. This Level 1 controlled study is being conducted across five countries in Europe and is expected […]

Read more

Intrinsic Therapeutics, Inc. names Cary P. Hagan as President and CEO

Intrinsic Therapeutics, a medical device company focused on developing therapies to address the spine market’s many unmet needs, today announced that Cary Hagan has been appointed President and Chief Executive Officer. Mr. Hagan brings over 20 years of experience in the orthopedic implant field with significant expertise in product development, commercialization and global marketing strategy. Greg Lambrecht, Founder […]

Read more

Intrinsic enrolls first patient in Barricaid trial

Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid® device. Barricaid is designed to prevent reherniations following lumbar discectomy, while allowing the surgeon to retain as much of the native nucleus as possible […]

Read more

If Barricaid is right for you, we can help.

Sign up to receive future updates and information on the Barricaid procedure.
  • This field is for validation purposes and should be left unchanged.